Showing 4991-5000 of 7317 results for "".
- New Computational System Evaluates Vitiligo Repigmentation Rateshttps://practicaldermatology.com/news/new-computational-system-evaluates-vitiligo-repigmentation-rates/2470766/A research team from Shenzhen People’s Hospital have developed a computational system for evaluating repigmentation rates in vitiligo patients, according to a new paper in the Journal of Investigative Dermatology. The retrospective study, conducted from June 2019 to November 2022
- National Rosacea Society Introduces Informational Postcardhttps://practicaldermatology.com/news/national-rosacea-society-introduces-informational-postcard/2470763/The National Rosacea Society (NRS) announced today that it has released a new educational postcard to raise awareness about rosacea, a chronic skin condition affecting over 16 million Americans. Titled “Rosacea: A Common Disease, Uncommonly Treated,” the resource is designed for d
- Key Thickness Benchmark Identified for Thin Melanoma Death Riskhttps://practicaldermatology.com/news/key-thickness-benchmark-identified-thin-melanoma-death-risk/2470668/Melanomas with Breslow thickness between 0.8 and 1.0 mm are associated with nearly triple the risk of melanoma-related death compared to thinner melanomas, a new study of Australian registry data reports. "Most patients who present with primary cutaneous melanomas have thin tumors (≤ 1.0 m
- AARS Scholar Grant to Be Used for Antibiotics Researchhttps://practicaldermatology.com/news/aars-scholar-grant-be-used-antibiotics-research/2470665/The American Acne and Rosacea Society (AARS) announced that the 2024 AARS Clinical Research Scholar Grant has been provided to Jean McGee, MD, PhD, of the Department of Dermatology at Brigham and Women’s Hospital in Boston. Additionally, AARS Clinical Research Grants are being provided to
- FDA Approves Tapinarof Cream, 1%, for ADhttps://practicaldermatology.com/news/fda-approves-tapinarof-cream-1-ad/2470664/The US Food and Drug Administration (FDA) approved tapinarof cream, 1%, an aryl hydrocarbon receptor agonist, for an additional indication of the topical treatment of atopic dermatitis (AD) in adults and pediatric patients 2 years of age and older, Organon announced. Organon received the FDA appr
- FDA Approves Nemluvio for Moderate-to-Severe Atopic Dermatitishttps://practicaldermatology.com/news/fda-approves-nemluvio-moderate-severe-atopic-dermatitis/2470663/Galderma’s Nemluvio® (nemolizumab) has received FDA approval for moderate-to-severe atopic dermatitis in patients aged 12 and older, offering a novel treatment option targeting IL-31. According to a press release from Galderma, the approval follows results from the phase III ARCADIA trial
- Veradermics Gets New Financing for AGA/PHL Candidatehttps://practicaldermatology.com/news/veradermics-gets-new-financing-agaphl-candidate/2468761/Veradermics announced the closing of a $75 million Series B financing, proceeds of which will be used to fund the ongoing clinical development of the company’s lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL). "The initiation of our pivota
- Psoriasis Linked with Education, Mood Disorders: Studyhttps://practicaldermatology.com/news/psoriasis-tied-education-and-mood-disorders-study/2468759/A new genetic study has identified six previously unreported loci associated with psoriasis, emphasizing its genetic complexity and links to socioeconomic and mental health factors. The analysis included data from 925,649 individuals across the FinnGen, Estonian Biobank, and UK Biobank, ma
- Advanced Neuroprotein Technique Linked with Improved Aesthetic Resultshttps://practicaldermatology.com/news/advanced-neuroprotein-technique-linked-improved-aesthetic-results/2468758/A study evaluating the use of botulinic neuroprotein combined with low molecular weight hyaluronic acid (LMWHA) and lyophilized amino acids in a single syringe showed enhanced outcomes in aesthetic treatments. The study included patients treated with a single injection session. According t
- FDA Clears Illuminate PRP System for Clinical Usehttps://practicaldermatology.com/news/fda-clears-illuminate-prp-system-clinical-use/2468757/Illuminate PRP’s platelet-rich plasma (PRP) system has received FDA clearance for clinical use, the company announced. The FDA-cleared single-spin PRP system offers a fast, efficient method for preparing high-quality PRP with high platelet capture rates, providing physicians with a reliabl